Ameriprise’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Ameriprise’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,845	Closed	-$42K	–	3758
2019 Q4	$42K	Buy	+1,845	New	+$26.3K	﹤0.01%	3682
2018 Q1	–	Sell	-34,392	Closed	-$2.51M	–	3706
2017 Q4	$2.51M	Sell	34,392 -267	-0.8%	-$22.1K	﹤0.01%	2549
2017 Q3	$3.18M	Buy	34,659 +23,374	+207%	+$1.79M	﹤0.01%	2380
2017 Q2	$746K	Sell	11,285 -4,629	-29%	-$573K	﹤0.01%	3077
2017 Q1	$3.45M	Buy	+15,914	New	+$2.27M	﹤0.01%	2293
2016 Q1	–	Sell	-9,300	Closed	-$3.05M	–	3888
2015 Q4	$3.05M	Buy	+9,300	New	+$3.03M	﹤0.01%	2365
2014 Q4	–	Hold	0	–	–	–	4487
2014 Q3	–	Sell	-3	Closed	-$660	–	5916
2014 Q2	$1K	Sell	3 -3,614	-100%	-$735K	﹤0.01%	5392
2014 Q1	$924K	Buy	+3,617	New	+$1.11M	﹤0.01%	2756
2013 Q4	–	Sell	-117	Closed	-$20K	–	5443
2013 Q3	$20K	Sell	117 -2	-2%	-$322	﹤0.01%	4424
2013 Q2	$21K	Buy	+119	New	+$16.9K	﹤0.01%	4256

Other funds holding LUMO

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

IFG

Investors Financial Group Plymouth, Minnesota $215M AUM 19.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's LUMO Position: Q1 2020 in Review

Ameriprise sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2020, closing a stake of 1,845 shares — an estimated $42K sold.

Ameriprise first reported a position in LUMO in Q2 2013 and held it in 10 quarters. The position peaked at $3.45M in Q1 2017. 46 funds tracked by Wall St. Rank hold LUMO as of Q1 2020.

Ameriprise reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Ameriprise sold 1,845 Lumos Pharma, Inc. Common Stock shares in Q1 2020, an estimated $42K.
Ameriprise first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 10 quarters.
Ameriprise's Lumos Pharma, Inc. Common Stock position peaked at $3.45M in Q1 2017.
46 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2020.

Based on Ameriprise's 13F filing for Q1 2020, filed 15 May 2020.